サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1525461

ゲノミクス向けAIの世界市場の評価：提供別、技術別、機能別、用途別、エンドユーザー別、地域別、機会、予測（2017年～2031年）

AI in Genomics Market Assessment, By Offering, By Technology, By Functionality, By Application, By End-user, By Region, Opportunities and Forecast, 2017-2031F

出版日
ページ情報
英文 229 Pages
納期
3～5営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=143.57円
ゲノミクス向けAIの世界市場の評価：提供別、技術別、機能別、用途別、エンドユーザー別、地域別、機会、予測（2017年～2031年）
出版日: 2024年08月02日
発行: Market Xcel - Markets and Data
ページ情報: 英文 229 Pages
納期: 3～5営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界のゲノミクス向けAIの市場規模は、2023年の6億3,360万米ドルから2031年に89億1,451万米ドルに達すると予測され、予測期間の2024年～2031年にCAGRで39.17％の成長が見込まれます。市場の成長は、AIの進歩、ゲノムデータの生成の増加、医薬品開発プロセスの迅速化に対する要求の高まり、慢性疾患患者の増加、老年人口の拡大によって支えられています。AIとゲノミクスの統合により、大量のデータを正確かつ時間効率の高い方法で分析することが可能になり、AIアルゴリズムが疾病リスクの予測、標的治療の開発、遺伝子変異の特定を支援することで、医療従事者がより充実した患者ケアを提供し、十分な情報に基づいた意思決定を行うことができるようになります。

個別化医療に対する要求の高まりも、世界のゲノミクス向けAIの市場成長を後押しする主な要因です。ゲノム情報は、研究者や科学者が薬剤に対する個々の反応を研究するのに役立つ一方で、AIとの統合により、大量のデータを時間効率よく分析できるようになるためです。AIアルゴリズムは、標的治療の開発、遺伝子変異の特定、疾病リスクの予測に役立ちます。

さらに、がん患者の増加も世界のゲノミクス向けAIの市場規模を拡大する大きな要因となっています。National Cancer Instituteの推計によると、米国では2024年に約200万1,140人のがん患者が新たに診断されると予測されています。この増加は、異常増殖の原因となる酵素反応の阻害、分子シグナル伝達経路の停止、遺伝子発現を担うがん細胞の特性の阻害を支援するがん関連薬の開発を支援するための、がん患者のゲノム変化の研究を含む研究活動への取り組みを推進しています。

医薬品開発プロセスの迅速化に対する要求の高まりが市場成長を後押し

高齢化の進行と遺伝性疾患、慢性疾患、感染症の増加により、医薬品開発プロセスの加速が不可欠となっています。世界保健機関（WHO）の推計によると、60歳以上の人口は2050年までに21億人に増加すると見込まれています。医薬品開発プロセスの探索段階で選択されたさまざまな医薬品候補は、好ましくない薬物動態特性や毒性のために後期段階を通過することができません。AIと機械学習の技術は、さまざまな遺伝子集団に対する薬剤の効果を分析し、開発期間を短縮することで、標的の検証と特定、バイオマーカーの発見、薬剤の再利用、臨床試験の最適化を支援します。AIモデルは、特定の経路や遺伝子を標的とすることの有効性を予測し、さまざまな薬剤の効果を刺激し、特定の患者グループが特定の治療にどのように反応するかを示すことができます。その結果、研究者は医薬品開発プロセスをスピードアップし、高まる要求に応えることができます。

ゲノムプロジェクトへの投資の増加が市場需要を押し上げる

さまざまな政府によるゲノミクスプロジェクトへの投資の増加は、AIが生成されたデータの分析を強化し加速するのに役立つことから、世界のゲノミクス向けAI市場の需要を押し上げる主な要因の1つとなっています。2024年2月、Department of BiotechnologyはGenome India Projectを完了し、1万のゲノムのシーケンシングを行ったと発表しました。全国の20の機関が99の民族から遺伝子サンプルを収集し、将来の研究活動に活用できる遺伝子データベースのリファレンスを作成しました。このような投資や取り組みは、ゲノムデータの生成を強化し、さまざまなAIアルゴリズムがデータの効果的な管理や複雑なデータセットの分析を可能にすることから、市場の成長を増大させています。

製薬企業・バイオテクノロジー企業が大きな市場シェアを占める

遺伝病患者の増加による製薬企業・バイオ企業の急拡大が、市場の成長を支えています。American Lung Associationの推計によると、米国では約3万人が嚢胞性線維症を患っており、米国人の約30人に1人が保因者です。機械学習とAIは、製薬企業やバイオテクノロジー企業が、潜在的な化合物の毒性を予測し、失敗する可能性の高い医薬品への使用を防ぐ臨床データの効率的な管理とともに、疾患の予測と予防を自動化することを支援します。その結果、企業は効果的な治療ソリューションに投資できるようになり、患者の転帰が向上します。

一方、病院は、個別化医療への投資の高まりと、大規模データセットの管理にAIを採用する動きが活発化していることから、今後数年間に大きな成長が見込まれます。

当レポートでは、世界のゲノミクス向けAI市場について調査分析し、市場規模と予測、各地域の市場見通し、市場力学、競合情勢などを提供しています。

目次

第1章 プロジェクトの範囲と定義

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 ゲノミクス向けAI市場の見通し（2017年～2031年）

  • 市場規模の分析と予測
    • 金額
  • 市場シェア分析と予測
    • 提供別
    • 技術別
    • 機能別
    • 用途別
    • エンドユーザー別
    • 地域別
    • 市場シェア分析：企業別（金額）（上位5社とその他 - 2023年）
  • 市場マップ分析（2023年）
    • 提供別
    • 技術別
    • 機能別
    • 用途別
    • エンドユーザー別
    • 地域別

第5章 北米のゲノミクス向けAI市場の見通し（2017年～2031年）

  • 市場規模の分析と予測
    • 金額
  • 市場シェア分析と予測
    • 提供別
    • 技術別
    • 機能別
    • 用途別
    • エンドユーザー別
    • シェア：国別
  • 市場の評価：国別
    • 米国のゲノミクス向けAI市場の見通し（2017年～2031年）
    • カナダ
    • メキシコ

第6章 欧州のゲノミクス向けAI市場の見通し（2017年～2031年）

  • ドイツ
  • フランス
  • イタリア
  • 英国
  • ロシア
  • オランダ
  • スペイン
  • ポーランド

第7章 アジア太平洋のゲノミクス向けAI市場の見通し（2017年～2031年）

  • インド
  • 中国
  • 日本
  • オーストラリア
  • ベトナム
  • 韓国
  • インドネシア
  • フィリピン

第8章 南米のゲノミクス向けAI市場の見通し（2017年～2031年）

  • ブラジル
  • アルゼンチン

第9章 中東・アフリカのゲノミクス向けAI市場の見通し（2017年～2031年）

  • サウジアラビア
  • アラブ首長国連邦
  • 南アフリカ
  • イスラエル

第10章 需給分析

第11章 輸入と輸出の分析

第12章 バリューチェーン分析

第13章 ポーターのファイブフォース分析

第14章 PESTLE分析

第15章 価格分析

第16章 市場力学

  • 市場促進要因
  • 市場の課題

第17章 市場の動向と発展

第18章 規制枠組みとイノベーション

  • 臨床試験
  • 規制当局の承認

第19章 特許情勢

第20章 ケーススタディ

第21章 競合情勢

  • マーケットリーダー上位5社の競合マトリクス
  • 上位5社のSWOT分析
  • 主要企業上位10社の情勢
    • Intel Services
    • Illumina, Inc.
    • Thermo Fisher Scientific Inc.
    • NVIDIA Corporation
    • Microsoft Corporation
    • International Business Machines Corporation
    • SOPHiA GENETICS
    • BenevolentAI Group
    • Helix, Inc.
    • Deep Genomics Incorporated

第22章 戦略的推奨

第23章 当社について、免責事項

図表

List of Tables

  • Table 1. Pricing Analysis of Products from Key Players
  • Table 2. Competition Matrix of Top 5 Market Leaders
  • Table 3. Mergers & Acquisitions/ Joint Ventures (If Applicable)
  • Table 4. About Us - Regions and Countries Where We Have Executed Client Projects

List of Figures

  • Figure 1. Global AI in Genomics Market, By Value, In USD Million, 2017-2031F
  • Figure 2. Global AI in Genomics Market Share (%), By Offering, 2017-2031F
  • Figure 3. Global AI in Genomics Market Share (%), By Technology, 2017-2031F
  • Figure 4. Global AI in Genomics Market Share (%), By Functionality, 2017-2031F
  • Figure 5. Global AI in Genomics Market Share (%), By Application, 2017-2031F
  • Figure 6. Global AI in Genomics Market Share (%), By End-user, 2017-2031F
  • Figure 7. Global AI in Genomics Market Share (%), By Region, 2017-2031F
  • Figure 8. North America AI in Genomics Market, By Value, In USD Million, 2017-2031F
  • Figure 9. North America AI in Genomics Market Share (%), By Offering, 2017-2031F
  • Figure 10. North America AI in Genomics Market Share (%), By Technology, 2017-2031F
  • Figure 11. North America AI in Genomics Market Share (%), By Functionality, 2017-2031F
  • Figure 12. North America AI in Genomics Market Share (%), By Application, 2017-2031F
  • Figure 13. North America AI in Genomics Market Share (%), By End-user, 2017-2031F
  • Figure 14. North America AI in Genomics Market Share (%), By Country, 2017-2031F
  • Figure 15. United States AI in Genomics Market, By Value, In USD Million, 2017-2031F
  • Figure 16. United States AI in Genomics Market Share (%), By Offering, 2017-2031F
  • Figure 17. United States AI in Genomics Market Share (%), By Technology, 2017-2031F
  • Figure 18. United States AI in Genomics Market Share (%), By Functionality, 2017-2031F
  • Figure 19. United States AI in Genomics Market Share (%), By Application, 2017-2031F
  • Figure 20. United States AI in Genomics Market Share (%), By End-user, 2017-2031F
  • Figure 21. Canada AI in Genomics Market, By Value, In USD Million, 2017-2031F
  • Figure 22. Canada AI in Genomics Market Share (%), By Offering, 2017-2031F
  • Figure 23. Canada AI in Genomics Market Share (%), By Technology, 2017-2031F
  • Figure 24. Canada AI in Genomics Market Share (%), By Functionality, 2017-2031F
  • Figure 25. Canada AI in Genomics Market Share (%), By Application, 2017-2031F
  • Figure 26. Canada AI in Genomics Market Share (%), By End-user, 2017-2031F
  • Figure 27. Mexico AI in Genomics Market, By Value, In USD Million, 2017-2031F
  • Figure 28. Mexico AI in Genomics Market Share (%), By Offering, 2017-2031F
  • Figure 29. Mexico AI in Genomics Market Share (%), By Technology, 2017-2031F
  • Figure 30. Mexico AI in Genomics Market Share (%), By Functionality, 2017-2031F
  • Figure 31. Mexico AI in Genomics Market Share (%), By Application, 2017-2031F
  • Figure 32. Mexico AI in Genomics Market Share (%), By End-user, 2017-2031F
  • Figure 33. Europe AI in Genomics Market, By Value, In USD Million, 2017-2031F
  • Figure 34. Europe AI in Genomics Market Share (%), By Offering, 2017-2031F
  • Figure 35. Europe AI in Genomics Market Share (%), By Technology, 2017-2031F
  • Figure 36. Europe AI in Genomics Market Share (%), By Functionality, 2017-2031F
  • Figure 37. Europe AI in Genomics Market Share (%), By Application, 2017-2031F
  • Figure 38. Europe AI in Genomics Market Share (%), By End-user, 2017-2031F
  • Figure 39. Europe AI in Genomics Market Share (%), By Country, 2017-2031F
  • Figure 40. Germany AI in Genomics Market, By Value, In USD Million, 2017-2031F
  • Figure 41. Germany AI in Genomics Market Share (%), By Offering, 2017-2031F
  • Figure 42. Germany AI in Genomics Market Share (%), By Technology, 2017-2031F
  • Figure 43. Germany AI in Genomics Market Share (%), By Functionality, 2017-2031F
  • Figure 44. Germany AI in Genomics Market Share (%), By Application, 2017-2031F
  • Figure 45. Germany AI in Genomics Market Share (%), By End-user, 2017-2031F
  • Figure 46. France AI in Genomics Market, By Value, In USD Million, 2017-2031F
  • Figure 47. France AI in Genomics Market Share (%), By Offering, 2017-2031F
  • Figure 48. France AI in Genomics Market Share (%), By Technology, 2017-2031F
  • Figure 49. France AI in Genomics Market Share (%), By Functionality, 2017-2031F
  • Figure 50. France AI in Genomics Market Share (%), By Application, 2017-2031F
  • Figure 51. France AI in Genomics Market Share (%), By End-user, 2017-2031F
  • Figure 52. Italy AI in Genomics Market, By Value, In USD Million, 2017-2031F
  • Figure 53. Italy AI in Genomics Market Share (%), By Offering, 2017-2031F
  • Figure 54. Italy AI in Genomics Market Share (%), By Technology, 2017-2031F
  • Figure 55. Italy AI in Genomics Market Share (%), By Functionality, 2017-2031F
  • Figure 56. Italy AI in Genomics Market Share (%), By Application, 2017-2031F
  • Figure 57. Italy AI in Genomics Market Share (%), By End-user, 2017-2031F
  • Figure 58. United Kingdom AI in Genomics Market, By Value, In USD Million, 2017-2031F
  • Figure 59. United Kingdom AI in Genomics Market Share (%), By Offering, 2017-2031F
  • Figure 60. United Kingdom AI in Genomics Market Share (%), By Technology, 2017-2031F
  • Figure 61. United Kingdom AI in Genomics Market Share (%), By Functionality, 2017-2031F
  • Figure 62. United Kingdom AI in Genomics Market Share (%), By Application, 2017-2031F
  • Figure 63. United Kingdom AI in Genomics Market Share (%), By End-user, 2017-2031F
  • Figure 64. Russia AI in Genomics Market, By Value, In USD Million, 2017-2031F
  • Figure 65. Russia AI in Genomics Market Share (%), By Offering, 2017-2031F
  • Figure 66. Russia AI in Genomics Market Share (%), By Technology, 2017-2031F
  • Figure 67. Russia AI in Genomics Market Share (%), By Functionality, 2017-2031F
  • Figure 68. Russia AI in Genomics Market Share (%), By Application, 2017-2031F
  • Figure 69. Russia AI in Genomics Market Share (%), By End-user, 2017-2031F
  • Figure 70. Netherlands AI in Genomics Market, By Value, In USD Million, 2017-2031F
  • Figure 71. Netherlands AI in Genomics Market Share (%), By Offering, 2017-2031F
  • Figure 72. Netherlands AI in Genomics Market Share (%), By Technology, 2017-2031F
  • Figure 73. Netherlands AI in Genomics Market Share (%), By Functionality, 2017-2031F
  • Figure 74. Netherlands AI in Genomics Market Share (%), By Application, 2017-2031F
  • Figure 75. Netherlands AI in Genomics Market Share (%), By End-user, 2017-2031F
  • Figure 76. Spain AI in Genomics Market, By Value, In USD Million, 2017-2031F
  • Figure 77. Spain AI in Genomics Market Share (%), By Offering, 2017-2031F
  • Figure 78. Spain AI in Genomics Market Share (%), By Technology, 2017-2031F
  • Figure 79. Spain AI in Genomics Market Share (%), By Functionality, 2017-2031F
  • Figure 80. Spain AI in Genomics Market Share (%), By Application, 2017-2031F
  • Figure 81. Spain AI in Genomics Market Share (%), By End-user, 2017-2031F
  • Figure 82. Turkey AI in Genomics Market, By Value, In USD Million, 2017-2031F
  • Figure 83. Turkey AI in Genomics Market Share (%), By Offering, 2017-2031F
  • Figure 84. Turkey AI in Genomics Market Share (%), By Technology, 2017-2031F
  • Figure 85. Turkey AI in Genomics Market Share (%), By Functionality, 2017-2031F
  • Figure 86. Turkey AI in Genomics Market Share (%), By Application, 2017-2031F
  • Figure 87. Turkey AI in Genomics Market Share (%), By End-user, 2017-2031F
  • Figure 88. Poland AI in Genomics Market, By Value, In USD Million, 2017-2031F
  • Figure 89. Poland AI in Genomics Market Share (%), By Offering, 2017-2031F
  • Figure 90. Poland AI in Genomics Market Share (%), By Technology, 2017-2031F
  • Figure 91. Poland AI in Genomics Market Share (%), By Functionality, 2017-2031F
  • Figure 92. Poland AI in Genomics Market Share (%), By Application, 2017-2031F
  • Figure 93. Poland AI in Genomics Market Share (%), By End-user, 2017-2031F
  • Figure 94. South America AI in Genomics Market, By Value, In USD Million, 2017-2031F
  • Figure 95. South America AI in Genomics Market Share (%), By Offering, 2017-2031F
  • Figure 96. South America AI in Genomics Market Share (%), By Technology, 2017-2031F
  • Figure 97. South America AI in Genomics Market Share (%), By Functionality, 2017-2031F
  • Figure 98. South America AI in Genomics Market Share (%), By Application, 2017-2031F
  • Figure 99. South America AI in Genomics Market Share (%), By End-user, 2017-2031F
  • Figure 100. South America AI in Genomics Market Share (%), By Country, 2017-2031F
  • Figure 101. Brazil AI in Genomics Market, By Value, In USD Million, 2017-2031F
  • Figure 102. Brazil AI in Genomics Market Share (%), By Offering, 2017-2031F
  • Figure 103. Brazil AI in Genomics Market Share (%), By Technology, 2017-2031F
  • Figure 104. Brazil AI in Genomics Market Share (%), By Functionality, 2017-2031F
  • Figure 105. Brazil AI in Genomics Market Share (%), By Application, 2017-2031F
  • Figure 106. Brazil AI in Genomics Market Share (%), By End-user, 2017-2031F
  • Figure 107. Argentina AI in Genomics Market, By Value, In USD Million, 2017-2031F
  • Figure 108. Argentina AI in Genomics Market Share (%), By Offering, 2017-2031F
  • Figure 109. Argentina AI in Genomics Market Share (%), By Technology, 2017-2031F
  • Figure 110. Argentina AI in Genomics Market Share (%), By Functionality, 2017-2031F
  • Figure 111. Argentina AI in Genomics Market Share (%), By Application, 2017-2031F
  • Figure 112. Argentina AI in Genomics Market Share (%), By End-user, 2017-2031F
  • Figure 113. Asia-Pacific AI in Genomics Market, By Value, In USD Million, 2017-2031F
  • Figure 114. Asia-Pacific AI in Genomics Market Share (%), By Offering, 2017-2031F
  • Figure 115. Asia-Pacific AI in Genomics Market Share (%), By Technology, 2017-2031F
  • Figure 116. Asia-Pacific AI in Genomics Market Share (%), By Functionality, 2017-2031F
  • Figure 117. Asia-Pacific AI in Genomics Market Share (%), By Application, 2017-2031F
  • Figure 118. Asia-Pacific AI in Genomics Market Share (%), By End-user, 2017-2031F
  • Figure 119. Asia-Pacific AI in Genomics Market Share (%), By Country, 2017-2031F
  • Figure 120. India AI in Genomics Market, By Value, In USD Million, 2017-2031F
  • Figure 121. India AI in Genomics Market Share (%), By Offering, 2017-2031F
  • Figure 122. India AI in Genomics Market Share (%), By Technology, 2017-2031F
  • Figure 123. India AI in Genomics Market Share (%), By Functionality, 2017-2031F
  • Figure 124. India AI in Genomics Market Share (%), By Application, 2017-2031F
  • Figure 125. India AI in Genomics Market Share (%), By End-user, 2017-2031F
  • Figure 126. China AI in Genomics Market, By Value, In USD Million, 2017-2031F
  • Figure 127. China AI in Genomics Market Share (%), By Offering, 2017-2031F
  • Figure 128. China AI in Genomics Market Share (%), By Technology, 2017-2031F
  • Figure 129. China AI in Genomics Market Share (%), By Functionality, 2017-2031F
  • Figure 130. China AI in Genomics Market Share (%), By Application, 2017-2031F
  • Figure 131. China AI in Genomics Market Share (%), By End-user, 2017-2031F
  • Figure 132. Japan AI in Genomics Market, By Value, In USD Million, 2017-2031F
  • Figure 133. Japan AI in Genomics Market Share (%), By Offering, 2017-2031F
  • Figure 134. Japan AI in Genomics Market Share (%), By Technology, 2017-2031F
  • Figure 135. Japan AI in Genomics Market Share (%), By Functionality, 2017-2031F
  • Figure 136. Japan AI in Genomics Market Share (%), By Application, 2017-2031F
  • Figure 137. Japan AI in Genomics Market Share (%), By End-user, 2017-2031F
  • Figure 138. Australia AI in Genomics Market, By Value, In USD Million, 2017-2031F
  • Figure 139. Australia AI in Genomics Market Share (%), By Offering, 2017-2031F
  • Figure 140. Australia AI in Genomics Market Share (%), By Technology, 2017-2031F
  • Figure 141. Australia AI in Genomics Market Share (%), By Functionality, 2017-2031F
  • Figure 142. Australia AI in Genomics Market Share (%), By Application, 2017-2031F
  • Figure 143. Australia AI in Genomics Market Share (%), By End-user, 2017-2031F
  • Figure 144. Vietnam AI in Genomics Market, By Value, In USD Million, 2017-2031F
  • Figure 145. Vietnam AI in Genomics Market Share (%), By Offering, 2017-2031F
  • Figure 146. Vietnam AI in Genomics Market Share (%), By Technology, 2017-2031F
  • Figure 147. Vietnam AI in Genomics Market Share (%), By Functionality, 2017-2031F
  • Figure 148. Vietnam AI in Genomics Market Share (%), By Application, 2017-2031F
  • Figure 149. Vietnam AI in Genomics Market Share (%), By End-user, 2017-2031F
  • Figure 150. South Korea AI in Genomics Market, By Value, In USD Million, 2017-2031F
  • Figure 151. South Korea AI in Genomics Market Share (%), By Offering, 2017-2031F
  • Figure 152. South Korea AI in Genomics Market Share (%), By Technology, 2017-2031F
  • Figure 153. South Korea AI in Genomics Market Share (%), By Functionality, 2017-2031F
  • Figure 154. South Korea AI in Genomics Market Share (%), By Application, 2017-2031F
  • Figure 155. South Korea AI in Genomics Market Share (%), By End-user, 2017-2031F
  • Figure 156. Indonesia AI in Genomics Market, By Value, In USD Million, 2017-2031F
  • Figure 157. Indonesia AI in Genomics Market Share (%), By Offering, 2017-2031F
  • Figure 158. Indonesia AI in Genomics Market Share (%), By Technology, 2017-2031F
  • Figure 159. Indonesia AI in Genomics Market Share (%), By Functionality, 2017-2031F
  • Figure 160. Indonesia AI in Genomics Market Share (%), By Application, 2017-2031F
  • Figure 161. Indonesia AI in Genomics Market Share (%), By End-user, 2017-2031F
  • Figure 162. Philippines AI in Genomics Market, By Value, In USD Million, 2017-2031F
  • Figure 163. Philippines AI in Genomics Market Share (%), By Offering, 2017-2031F
  • Figure 164. Philippines AI in Genomics Market Share (%), By Technology, 2017-2031F
  • Figure 165. Philippines AI in Genomics Market Share (%), By Functionality, 2017-2031F
  • Figure 166. Philippines AI in Genomics Market Share (%), By Application, 2017-2031F
  • Figure 167. Philippines AI in Genomics Market Share (%), By End-user, 2017-2031F
  • Figure 168. Middle East & Africa AI in Genomics Market, By Value, In USD Million, 2017-2031F
  • Figure 169. Middle East & Africa AI in Genomics Market Share (%), By Offering, 2017-2031F
  • Figure 170. Middle East & Africa AI in Genomics Market Share (%), By Technology, 2017-2031F
  • Figure 171. Middle East & Africa AI in Genomics Market Share (%), By Functionality, 2017-2031F
  • Figure 172. Middle East & Africa AI in Genomics Market Share (%), By Application, 2017-2031F
  • Figure 173. Middle East & Africa AI in Genomics Market Share (%), By End-user, 2017-2031F
  • Figure 174. Middle East & Africa AI in Genomics Market Share (%), By Country, 2017-2031F
  • Figure 175. Saudi Arabia AI in Genomics Market, By Value, In USD Million, 2017-2031F
  • Figure 176. Saudi Arabia AI in Genomics Market Share (%), By Offering, 2017-2031F
  • Figure 177. Saudi Arabia AI in Genomics Market Share (%), By Technology, 2017-2031F
  • Figure 178. Saudi Arabia AI in Genomics Market Share (%), By Functionality, 2017-2031F
  • Figure 179. Saudi Arabia AI in Genomics Market Share (%), By Application, 2017-2031F
  • Figure 180. Saudi Arabia AI in Genomics Market Share (%), By End-user, 2017-2031F
  • Figure 181. UAE AI in Genomics Market, By Value, In USD Million, 2017-2031F
  • Figure 182. UAE AI in Genomics Market Share (%), By Offering, 2017-2031F
  • Figure 183. UAE AI in Genomics Market Share (%), By Technology, 2017-2031F
  • Figure 184. UAE AI in Genomics Market Share (%), By Functionality, 2017-2031F
  • Figure 185. UAE AI in Genomics Market Share (%), By Application, 2017-2031F
  • Figure 186. UAE AI in Genomics Market Share (%), By End-user, 2017-2031F
  • Figure 187. South Africa AI in Genomics Market, By Value, In USD Million, 2017-2031F
  • Figure 188. South Africa AI in Genomics Market Share (%), By Offering, 2017-2031F
  • Figure 189. South Africa AI in Genomics Market Share (%), By Technology, 2017-2031F
  • Figure 190. South Africa AI in Genomics Market Share (%), By Functionality, 2017-2031F
  • Figure 191. South Africa AI in Genomics Market Share (%), By Application, 2017-2031F
  • Figure 192. South Africa AI in Genomics Market Share (%), By End-user, 2017-2031F
  • Figure 193. By Offering Map-Market Size (USD Million) & Growth Rate (%), 2023
  • Figure 194. By Technology Map-Market Size (USD Million) & Growth Rate (%), 2023
  • Figure 195. By Functionality Map-Market Size (USD Million) & Growth Rate (%), 2023
  • Figure 196. By Application Map-Market Size (USD Million) & Growth Rate (%), 2023
  • Figure 197. By End-user Map-Market Size (USD Million) & Growth Rate (%), 2023
  • Figure 198. By Region Map-Market Size (USD Million) & Growth Rate (%), 2023
目次
Product Code: MX11682

Global AI in genomics market is projected to witness a CAGR of 39.17% during the forecast period 2024-2031, growing from USD 633.60 million in 2023 to USD 8914.51 million in 2031. The market's growth is supported by the advancements in artificial intelligence (AI), rising generation of genomic data, growing requirement for acceleration of drug development processes, increasing cases of chronic diseases, and expansion of geriatric population. The integration of AI with genomics allows the analyses of large amounts of data in an accurate and time efficient manner and AI algorithms aiding in predicting risk of diseases, developing targeted therapies, and identifying genetic mutations, allowing the healthcare professionals to provide enhanced patient care and making informed decisions.

The rising requirement for personalized medicines is another major factor boosting the global AI in genomics market growth as genomic information aids researchers and scientists in studying the individual responses to the drugs while the integration with AI allows for analyses of larger volumes of data in a time efficient manner. The AI algorithms aid in developing targeted therapies, identifying genetic mutations, and predicting the risk of disease.

Additionally, the increasing cases of cancer is another major factor augmenting the global AI in genomics market size. As per the estimates of the National Cancer Institute, approximately 2,001,140 new cases of cancer are expected to be diagnosed in 2024 in the United States. The increase is propelling the efforts towards the research activities, including research in genomic changes in cancer patients to support the development of cancer related drugs that aid in inhibiting enzyme responses responsible for abnormal growth, halting molecular signaling pathways, and blocking characteristics of cancer cells that are responsible for gene expression.

Rising Requirement for Accelerated Drug Development Process Boosts Market Growth

Due to the growth of aging population and rising cases of genetic, chronic, and infectious diseases, the acceleration of drug development process is becoming essential. According to the estimates of the World Health Organization (WHO), the population of individuals of age sixty and above is expected to increase to 2.1 billion, by 2050. Various drug candidates that are selected during the discovery phase of the drug development processes fail to cross late stages due to unfavorable pharmacokinetic properties and toxicity. AI and machine learning technologies aid in target validation and identification, discovery of biomarkers, repurposing of drugs, and optimization of clinical trials by analyzing the effects of drugs on various genetic populations and shortening the development timeline. The AI models can predict the effectiveness of targeting specific pathways and genes, stimulating the effects of different drugs and indicating how a certain group of patients respond to specific treatments. It in turn aids researchers in speeding the drug development process, allowing them to meet the rising requirements.

Increasing Investments Towards Genomic Projects Boosts Market Demand

The rising investments by different governments towards genomics projects is one of the major factors boosting the global AI in genomics market demand as AI aids in enhancing and accelerating the analysis of the generated data. In February 2024, the Department of Biotechnology announced that they had completed the Genome India Project and conducted sequencing of 10,000 genomes. Twenty institutions across the country collected gene samples from ninety-nine ethnic groups, creating a reference of genetic database for utilization in future research activities. Such investments and initiatives are bolstering the generation of genomic data and augmenting the growth of the market as various AI algorithms allow for effective management of data and analysis of complex data sets.

Pharmaceutical and Biotech Companies Hold Significant Market Share

The rapid expansion of pharmaceutical and biotech companies due to the increasing cases of genetic diseases is supporting the market's growth. As per the estimates of the American Lung Association, approximately 30,000 people in the United States have cystic fibrosis, and around 1 in 30 Americans is a carrier. Machine learning and artificial intelligence aid pharmaceutical and biotech companies to automate prediction and prevention of disease, along with efficient management of clinical data that predict toxicity of potential compounds, preventing them from use in drugs that have a higher probability of failing. It in turn will allow the companies to invest in effective therapeutic solutions, thus enhancing the patient outcomes.

Meanwhile, hospitals are expected to witness significant growth in the forecast years, it can be attributed to the rising investments in personalized medicines and rising adoption of AI for management of large data sets.

North America Expected to Hold Significant Market Share

The market growth in North America is supported by the strong presence of research institutions and biotech and genomic companies in the region, coupled with rising investments towards the development of AI powered solutions for applications in genomics. The rising investments in genomics can be attributed to the wide range of applications of the sector in healthcare and possible breakthroughs that could provide a cure for diseases and disorders that were earlier deemed without course or fatal. The rising prevalence of cancer in the region is another major factor, due to which investments in genomics are increasing, which in turn, is providing lucrative growth opportunities for the market. As per the estimates of the National Cancer Institute, 2,001,140 new cases of cancer are expected to be diagnosed in the United States in 2024.

Meanwhile, market is expected to witness significant growth in Asia-Pacific in the forecast years, owing to the increasing government initiatives in the region as genome sequencing in combination with phenotype, microbiome, and clinical information will allow for an enhanced analysis of healthy and disease affected individuals on the basis of inferred local ancestries.

Future Market Scenario (2024 - 2031F)

AI is expected to accelerate the analysis of massive genome sequencing data. The rising investments in research and development activities are expected to support the expansion of the market. The Hospital Universitari Vall d'Hebron Research Institute is conducting an observational study for improving the SCD prognosis and classification by AI. The study aims to advance disease characterization for improving health outcomes by developing individual models in sickle cell disease and identifying biomarkers. The development of the GENOMED4ALL AI algorithm for the sickle cell disease will allow in-depth characterization and the prediction of various complications associated with the disease. The primary endpoints of interest include the development of a probability score for predicting different patterns recognized by AI, development of predictive risk scores for occurrences of severe and prevalent clinical outcomes, and improved sickle cell disease classification. The study is expected to conclude in December 2024.

Key Players Landscape and Outlook

The growth of AI in genomics market is supported by the rising collaborations and partnerships between the key players of the market and leading biotechnology companies. In June 2024, Helix, Inc. announced partnership with Recursion Pharmaceuticals that will combine the company's clinic-genomic dataset with over 25 petabytes of the latter's chemical and biological data. Such collaborations will aid scientists in gathering more information about the correlation between genes and diseases and the availability of genetic information, allowing them to identify patients that could aid from preventive measures or specific treatments. This will aid healthcare professionals and reduce costs related to duplicate testing, resulting in efficient utilization of resources.

Table of Contents

1. Project Scope and Definitions

2. Research Methodology

3. Executive Summary

4. Global AI in Genomics Market Outlook, 2017-2031F

  • 4.1. Market Size Analysis & Forecast
    • 4.1.1. By Value
  • 4.2. Market Share Analysis & Forecast
    • 4.2.1. By Offering
      • 4.2.1.1. Software
      • 4.2.1.2. Services
    • 4.2.2. By Technology
      • 4.2.2.1. Machine Learning
        • 4.2.2.1.1. Deep Learning
        • 4.2.2.1.2. Supervised Learning
        • 4.2.2.1.3. Unsupervised Learning
        • 4.2.2.1.4. Reinforcement Learning
        • 4.2.2.1.5. Others
      • 4.2.2.2. Computer Vision
    • 4.2.3. By Functionality
      • 4.2.3.1. Genome Sequencing
      • 4.2.3.2. Clinical Workflow
      • 4.2.3.3. Predictive Genetic Testing and Preventive Medicine
      • 4.2.3.4. Gene Editing
    • 4.2.4. By Application
      • 4.2.4.1. Drug Discovery and Development
      • 4.2.4.2. Precision Medicine
      • 4.2.4.3. Diagnostics
      • 4.2.4.4. Agriculture and Animal Research
      • 4.2.4.5. Others
    • 4.2.5. By End-user
      • 4.2.5.1. Pharmaceutical and Biotech Companies
      • 4.2.5.2. Healthcare Providers
      • 4.2.5.3. Research Centers
      • 4.2.5.4. Others
    • 4.2.6. By Region
      • 4.2.6.1. North America
      • 4.2.6.2. Europe
      • 4.2.6.3. Asia-Pacific
      • 4.2.6.4. South America
      • 4.2.6.5. Middle East and Africa
    • 4.2.7. By Company Market Share Analysis (Top 5 Companies and Others - By Value, 2023)
  • 4.3. Market Map Analysis, 2023
    • 4.3.1. By Offering
    • 4.3.2. By Technology
    • 4.3.3. By Functionality
    • 4.3.4. By Application
    • 4.3.5. By End-user
    • 4.3.6. By Region

5. North America AI in Genomics Market Outlook, 2017-2031F*

  • 5.1. Market Size Analysis & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share Analysis & Forecast
    • 5.2.1. By Offering
      • 5.2.1.1. Software
      • 5.2.1.2. Services
    • 5.2.2. By Technology
      • 5.2.2.1. Machine Learning
        • 5.2.2.1.1. Deep Learning
        • 5.2.2.1.2. Supervised Learning
        • 5.2.2.1.3. Unsupervised Learning
        • 5.2.2.1.4. Reinforcement Learning
        • 5.2.2.1.5. Others
      • 5.2.2.2. Computer Vision
    • 5.2.3. By Functionality
      • 5.2.3.1. Genome Sequencing
      • 5.2.3.2. Clinical Workflow
      • 5.2.3.3. Predictive Genetic Testing and Preventive Medicine
      • 5.2.3.4. Gene Editing
    • 5.2.4. By Application
      • 5.2.4.1. Drug Discovery and Development
      • 5.2.4.2. Precision Medicine
      • 5.2.4.3. Diagnostics
      • 5.2.4.4. Agriculture and Animal Research
      • 5.2.4.5. Others
    • 5.2.5. By End-user
      • 5.2.5.1. Pharmaceutical and Biotech Companies
      • 5.2.5.2. Healthcare Providers
      • 5.2.5.3. Research Centers
      • 5.2.5.4. Others
    • 5.2.6. By Country Share
      • 5.2.6.1. United States
      • 5.2.6.2. Canada
      • 5.2.6.3. Mexico
  • 5.3. Country Market Assessment
    • 5.3.1. United States AI in Genomics Market Outlook, 2017-2031F*
      • 5.3.1.1. Market Size Analysis & Forecast
        • 5.3.1.1.1. By Value
      • 5.3.1.2. Market Share Analysis & Forecast
        • 5.3.1.2.1. By Offering
          • 5.3.1.2.1.1. Software
          • 5.3.1.2.1.2. Services
        • 5.3.1.2.2. By Technology
          • 5.3.1.2.2.1. Machine Learning
          • 5.3.1.2.2.1.1. Deep Learning
          • 5.3.1.2.2.1.2. Supervised Learning
          • 5.3.1.2.2.1.3. Unsupervised Learning
          • 5.3.1.2.2.1.4. Reinforcement Learning
          • 5.3.1.2.2.1.5. Others
          • 5.3.1.2.2.2. Computer Vision
        • 5.3.1.2.3. By Functionality
          • 5.3.1.2.3.1. Genome Sequencing
          • 5.3.1.2.3.2. Clinical Workflow
          • 5.3.1.2.3.3. Predictive Genetic Testing and Preventive Medicine
          • 5.3.1.2.3.4. Gene Editing
        • 5.3.1.2.4. By Application
          • 5.3.1.2.4.1. Drug Discovery and Development
          • 5.3.1.2.4.2. Precision Medicine
          • 5.3.1.2.4.3. Diagnostics
          • 5.3.1.2.4.4. Agriculture and Animal Research
          • 5.3.1.2.4.5. Others
        • 5.3.1.2.5. By End-user
          • 5.3.1.2.5.1. Pharmaceutical and Biotech Companies
          • 5.3.1.2.5.2. Healthcare Providers
          • 5.3.1.2.5.3. Research Centers
          • 5.3.1.2.5.4. Others
    • 5.3.2. Canada
    • 5.3.3. Mexico

All segments will be provided for all regions and countries covered

6. Europe AI in Genomics Market Outlook, 2017-2031F

  • 6.1. Germany
  • 6.2. France
  • 6.3. Italy
  • 6.4. United Kingdom
  • 6.5. Russia
  • 6.6. Netherlands
  • 6.7. Spain
  • 6.8. Poland

7. Asia-Pacific AI in Genomics Market Outlook, 2017-2031F

  • 7.1. India
  • 7.2. China
  • 7.3. Japan
  • 7.4. Australia
  • 7.5. Vietnam
  • 7.6. South Korea
  • 7.7. Indonesia
  • 7.8. Philippines

8. South America AI in Genomics Market Outlook, 2017-2031F

  • 8.1. Brazil
  • 8.2. Argentina

9. Middle East and Africa AI in Genomics Market Outlook, 2017-2031F

  • 9.1. Saudi Arabia
  • 9.2. UAE
  • 9.3. South Africa
  • 9.4. Israel

10. Demand Supply Analysis

11. Import and Export Analysis

12. Value Chain Analysis

13. Porter's Five Forces Analysis

14. PESTLE Analysis

15. Pricing Analysis

16. Market Dynamics

  • 16.1. Market Drivers
  • 16.2. Market Challenges

17. Market Trends and Developments

18. Regulatory Framework and Innovation

  • 18.1. Clinical Trials
  • 18.2. Regulatory Approvals

19. Patent Landscape

20. Case Studies

21. Competitive Landscape

  • 21.1. Competition Matrix of Top 5 Market Leaders
  • 21.2. SWOT Analysis for Top 5 Players
  • 21.3. Key Players Landscape for Top 10 Market Players
    • 21.3.1. Intel Services
      • 21.3.1.1. Company Details
      • 21.3.1.2. Key Management Personnel
      • 21.3.1.3. Products and Services
      • 21.3.1.4. Financials (As Reported)
      • 21.3.1.5. Key Market Focus and Geographical Presence
      • 21.3.1.6. Recent Developments/Collaborations/Partnerships/Mergers and Acquisition
    • 21.3.2. Illumina, Inc.
    • 21.3.3. Thermo Fisher Scientific Inc.
    • 21.3.4. NVIDIA Corporation
    • 21.3.5. Microsoft Corporation
    • 21.3.6. International Business Machines Corporation
    • 21.3.7. SOPHiA GENETICS
    • 21.3.8. BenevolentAI Group
    • 21.3.9. Helix, Inc.
    • 21.3.10. Deep Genomics Incorporated

Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work.

22. Strategic Recommendations

23. About Us and Disclaimer